BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Knopp EA, Cowper SE. Nephrogenic systemic fibrosis: early recognition and treatment. Semin Dial 2008;21:123-8. [PMID: 18226008 DOI: 10.1111/j.1525-139X.2007.00399.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 11] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Ferreli C, Gasparini G, Parodi A, Cozzani E, Rongioletti F, Atzori L. Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review. Clin Rev Allergy Immunol 2017;53:306-36. [PMID: 28712039 DOI: 10.1007/s12016-017-8625-4] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 21.0] [Reference Citation Analysis]
2 Russo M, Bevilacqua P, Netti PA, Torino E. A Microfluidic Platform to design crosslinked Hyaluronic Acid Nanoparticles (cHANPs) for enhanced MRI. Sci Rep 2016;6:37906. [PMID: 27901092 DOI: 10.1038/srep37906] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
3 Wagner B, Drel V, Gorin Y. Pathophysiology of gadolinium-associated systemic fibrosis. Am J Physiol Renal Physiol 2016;311:F1-F11. [PMID: 27147669 DOI: 10.1152/ajprenal.00166.2016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
4 Chopra T, Kandukurti K, Shah S, Ahmed R, Panesar M. Understanding nephrogenic systemic fibrosis. Int J Nephrol. 2012;2012:912189. [PMID: 23193473 DOI: 10.1155/2012/912189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
5 Do C, Barnes JL, Tan C, Wagner B. Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 2014;307:F844-55. [PMID: 25100280 DOI: 10.1152/ajprenal.00379.2014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
6 Lohani S, Golenbiewski J, Swami A, Halalau A. A unique case of nephrogenic systemic fibrosis from gadolinium exposure in a patient with normal eGFR. BMJ Case Rep 2017;2017:bcr-2017-221016. [PMID: 29025775 DOI: 10.1136/bcr-2017-221016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
7 Do C, Drel V, Tan C, Lee D, Wagner B. Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2. J Invest Dermatol 2019;139:2134-2143.e2. [PMID: 30978353 DOI: 10.1016/j.jid.2019.03.1145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Leung N, Pittelkow MR, Lee CU, Good JA, Hanley MM, Moyer TP. Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis. NDT Plus 2009;2:309-11. [PMID: 25984024 DOI: 10.1093/ndtplus/sfp042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
9 Villaraza AJ, Bumb A, Brechbiel MW. Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics. Chem Rev 2010;110:2921-59. [PMID: 20067234 DOI: 10.1021/cr900232t] [Cited by in Crossref: 466] [Cited by in F6Publishing: 404] [Article Influence: 42.4] [Reference Citation Analysis]
10 Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. Indian J Dermatol 2011;56:59-64. [PMID: 21572795 DOI: 10.4103/0019-5154.77555] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
11 Zelasko S, Hollingshead M, Castillo M, Bouldin TW. CT and MR imaging of progressive dural involvement by nephrogenic systemic fibrosis. AJNR Am J Neuroradiol 2008;29:1880-2. [PMID: 18854445 DOI: 10.3174/ajnr.A1225] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]